These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33240439)

  • 41. Is there a relationship in-between ovarian endometriosis and ovarian cancer? Immunohistochemical profile of four cases with coexisting ovarian endometriosis and cancer.
    Penciu RC; Postolache I; Steriu L; Izvoranu S; Tica AA; Mocanu ID; Sârbu V; Deacu M; Tica I; Bălţătescu GI; Tica OS; Tica VI
    Rom J Morphol Embryol; 2020; 61(1):157-165. PubMed ID: 32747907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 43. Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.
    Wiedemeyer WR; Beach JA; Karlan BY
    Front Oncol; 2014; 4():34. PubMed ID: 24624361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
    Endris V; Stenzinger A; Pfarr N; Penzel R; Möbs M; Lenze D; Darb-Esfahani S; Hummel M; Sabine-Merkelbach-Bruse ; Jung A; Lehmann U; Kreipe H; Kirchner T; Büttner R; Jochum W; Höfler G; Dietel M; Weichert W; Schirmacher P
    Virchows Arch; 2016 Jun; 468(6):697-705. PubMed ID: 27003155
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
    Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathogenesis and heterogeneity of ovarian cancer.
    Kroeger PT; Drapkin R
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):26-34. PubMed ID: 27898521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.
    Liu H; Zhang Z; Chen L; Pang J; Wu H; Liang Z
    Front Oncol; 2021; 11():798173. PubMed ID: 35096598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
    Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
    Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients.
    Gallardo-Rincón D; Álvarez-Gómez RM; Montes-Servín E; Toledo-Leyva A; Montes-Servín E; Michel-Tello D; Alamilla-García G; Bahena-González A; Hernández-Nava E; Fragoso-Ontiveros V; Espinosa-Romero R; Cetina-Pérez L
    Transl Oncol; 2020 Feb; 13(2):212-220. PubMed ID: 31869745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    Dong F; Davineni PK; Howitt BE; Beck AH
    Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients.
    Barbosa A; Pinto P; Peixoto A; Guerra J; Pinheiro M; Santos C; Pinto C; Escudeiro C; Bartosch C; Santos R; Brandão A; Silva J; Teixeira MR
    Front Oncol; 2021; 11():754094. PubMed ID: 34660321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
    Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
    Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clonal Evolution of
    Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
    Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
    Hollis RL; Meynert AM; Churchman M; Rye T; Mackean M; Nussey F; Arends MJ; Sims AH; Semple CA; Herrington CS; Gourley C
    BMC Cancer; 2018 Jan; 18(1):16. PubMed ID: 29298688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
    Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-grade serous ovarian carcinoma and detection of inactivated BRCA genes from biopsy material of Slovak patients.
    Janíková K; Váňová B; Grendár M; Samec M; Líšková A; Loderer D; Kašubová I; Farkašová A; Scheerova K; Slávik P; Lasabová Z; Danková Z; Plank L
    Neoplasma; 2021 Sep; 68(5):1107-1112. PubMed ID: 34263651
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic characterization of early onset ovarian carcinoma.
    Bernards SS; Norquist BM; Harrell MI; Agnew KJ; Lee MK; Walsh T; Swisher EM
    Gynecol Oncol; 2016 Feb; 140(2):221-5. PubMed ID: 26718727
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.